Key result
Remdesivir treatment in COVID-19 is linked to transient bradycardia as an adverse event.
Why the study?
Knowledge about remdesivir-related adverse events, especially cardiologic effects, in COVID-19 patients is scarce and mostly limited to case reports.
Key points are not available for this paper at this time.
Design
Experience report on COVID-19 treatment with remdesivir focusing on cardiologic adverse events
2] though RDV treatment was quite well described, 4-6 the knowledge about RDV-related adverse events is still scarce and mostly limited to case reports describing hepatotoxicity and skin reactions. Here, we describe our experience about COVID-19 treatment with RDV focusing on possible RDV-related cardiologic adverse events.
No takes yet. Share an insight, caveat, or question.
Pallotto et al. (2021) studied this question. Remdesivir treatment in patients with COVID-19 is potentially associated with transient bradycardia as a cardiologic adverse event.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: